| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-10 |
4 |
D |
$294.33 |
$1,018,676 |
D/D |
(3,461) |
65,184 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,108 |
65,697 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
AS |
$247.73 |
$1,171,842 |
D/D |
(4,660) |
65,697 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,568 |
68,645 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
AS |
$300.39 |
$399,022 |
D/D |
(1,304) |
68,645 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
69,949 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-12 |
4 |
AS |
$149.23 |
$965,671 |
D/D |
(6,403) |
69,999 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-05-15 |
4 |
AS |
$155.78 |
$15,266 |
D/D |
(98) |
69,999 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
31,020 |
70,133 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
38,757 |
70,310 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
AS |
$238.74 |
$604,775 |
D/D |
(2,526) |
70,310 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
OE |
$86.52 |
$403,183 |
D/D |
4,660 |
70,357 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$434,614 |
D/D |
2,526 |
72,836 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-01-12 |
4 |
A |
$0.01 |
$750 |
D/D |
75,000 |
75,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-11-18 |
4 |
AS |
$130.00 |
$1,950,000 |
D/D |
(15,000) |
75,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-12-01 |
4 |
AS |
$131.00 |
$655,000 |
D/D |
(5,000) |
75,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
26,641 |
76,402 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-12-01 |
4 |
OE |
$72.14 |
$360,700 |
D/D |
5,000 |
80,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-06-29 |
4 |
OE |
$86.52 |
$1,171,397 |
D/D |
13,445 |
83,444 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2016-02-02 |
4 |
A |
$0.01 |
$144 |
D/D |
14,416 |
89,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-11-18 |
4 |
OE |
$63.14 |
$1,014,600 |
D/D |
15,000 |
90,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-02-13 |
4 |
AS |
$87.68 |
$561,415 |
D/D |
(6,403) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-04-28 |
4 |
AS |
$120.00 |
$900,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-05-15 |
4 |
AS |
$114.37 |
$20,701 |
D/D |
(181) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-06-05 |
4 |
AS |
$130.00 |
$975,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
157 Records found
|
|
Page 6 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
